This application is designed to evaluate two promising approaches to the treatment of prolonged and frequent episodes of breakthrough bleeding which sometimes accompany the use of the implantable, progestogen-only implant Implanon. These erratic episodes of bleeding can be a major reason for discontinuation of use. There is increasing evidence that continuous exposure to progestogens results in a tendency for the endometrium to release active enzymes called matrix metalloproteinases [MMPs] which can promote premature breakdown of the tissue. Inhibition of the action of these enzymes may stabilize the endometrium and improve the bleeding pattern. A commonly used tetracycline compound, Doxycycline, has strong anti-MMP action and preliminary evidence in a mouse model of menstruation suggests that it may indeed stabilize the endometrium. There is preliminary evidence that a short course of an antiprogesterone (Mifepristone) may also stabilize the endometrium, and it is postulated that a combination of an antiprogesterone with estrogen may be even more effective. Preliminary evidence in mice indicates that estrogen exposure of the endometrium in the absence of progesterone strongly inhibits the formation of new blood vessels and simultaneous anti-progesterone exposure will mimic this situation. Antiprogesterones probably also have a direct effect in inhibiting angiogenesis, and the combination maybe a clinically valuable treatment. A triple combination of antiprogesterone, estrogen and anti MMP agent may have additive effects because of the likelihood of differing actions. This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD043192-02
Application #
6668685
Study Section
Special Emphasis Panel (ZHD1-DRG-D (16))
Program Officer
Mackay, H Trent
Project Start
2002-09-27
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
2
Fiscal Year
2003
Total Cost
$270,000
Indirect Cost
Name
Sydney Centre for Reproductive Health Research
Department
Type
DUNS #
City
Ashfield
State
Country
Australia
Zip Code
Maridas, David E; Hey-Cunningham, Alison J; Ng, Cecilia H M et al. (2014) Peripheral and endometrial dendritic cell populations during the normal cycle and in the presence of endometriosis. J Endometr Pelvic Pain Disord 6:67-119
Weisberg, E; Hickey, M; Palmer, D et al. (2009) A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 24:1852-61
Hickey, Martha; Salamonsen, Lois A (2008) Endometrial structural and inflammatory changes with exogenous progestogens. Trends Endocrinol Metab 19:167-74
Morison, Naomi B; Kaitu'u-Lino, Tu'uhevaha J; Fraser, Ian S et al. (2008) Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. Reproduction 136:267-74
Morison, Naomi B; Zhang, Jin; Kaitu'u-Lino, Tu'uhevaha J et al. (2007) The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women. Reproduction 133:309-21
Peloggia, Alessandra; Petta, Carlos A; Bahamondes, Luis et al. (2006) Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 21:1129-34
Weisberg, E; Hickey, M; Palmer, D et al. (2006) A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 21:295-302
Juul, Sandra E; Christensen, Robert D (2003) Absorption of enteral recombinant human erythropoietin by neonates. Ann Pharmacother 37:782-6
Juul, S (2002) Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 91:36-42